Cardiovascular Licensing Deal Calculator —
benchmark your deal in 60 seconds
Phase 2 CV deals median ~$40M upfront, ~$500M total. Rare CV (e.g., ATTR-CM) commands oncology-level multiples. Built on 1,900+ verified biopharma transactions across 12 therapeutic areas.
Cardiovascular deal benchmarks at a glance
Median deal terms for cardiovascular licensing transactions, by development phase. Data current as of 2026.
| Phase | Median Upfront | Median Total Value | Median Royalty (Tiered) |
|---|---|---|---|
| Preclinical | $35M | $500M | 4–8% |
| Phase 1 | $85M | $800M | 6–12% |
| Phase 2 | $250M | $1.8B | 8–16% |
| Phase 3 | $550M | $3.2B | 12–22% |
Source: Ambrosia Benchmarker dataset, 1,900+ verified transactions (2017–2026). Primary sources: SEC EDGAR 8-K filings, FTC premerger notifications, ClinicalTrials.gov.
Recent comparable deals
- BMS–MyoKardia ($13.1B, mavacamten)
- Lilly–Versanis
- Novartis–Cadence
Why Cardiovascular is priced this way
CV has been a quiet space but is heating up with Lp(a) inhibitors, PCSK9 follow-ons, and ATTR amyloidosis programs. Smaller upfronts than oncology but larger commercial tails.
Try it live
Run a Cardiovascular deal scenario
Pick your phase, modality, and indication. Get instant benchmark ranges — no signup needed to start.
Quick Benchmark
Live data from 1,900+ deals. Select your parameters:
Cardiovascular licensing — frequently asked
What is the median upfront payment for a Cardiovascular licensing deal?
How are Cardiovascular deal milestones structured?
What royalty rates are typical for Cardiovascular licensing?
Is there a free Cardiovascular deal calculator?
How does Cardiovascular licensing compare to other therapeutic areas?
7-Day Free Trial · No Promo Code
Run unlimited cardiovascular deals — Pro.
Monte Carlo sensitivity, partner matching across 850+ companies, scenario comparison (Bear/Base/Bull rNPV), and board-ready PDF reports. Free for 7 days. Cancel anytime.
Then $299/month · No charge during trial · Cancel anytime